CapsoVision (CV) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed CapsoVision (CV) over the past year, gaining 127.1% versus a gain of 38.9%. CapsoVision is the larger company by market cap ($352.3 million vs $85.0 million), about 4.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | NRXS |
|---|---|---|
| Share price | $6.62 | $6.77 |
| Market cap | $352.25M | $85.02M |
| 1-day change | +1.22% | -0.88% |
| YTD return | -38.82% | +50.44% |
| 1-year return | +38.85% | +127.14% |
| EPS (TTM) | $-0.45 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.37 | $9.33 |
| 52-week low | $4.38 | $2.21 |
| Distance from 52-week high | -56.93% | -27.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +43.50% | +62.48% |
| Average volume | 157.18K | 107.27K |
| Shares outstanding | 53.21M | 12.56M |
| Employees | 99 | 24 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CapsoVision is about 4.1 times larger than Neuraxis by market value ($352.25M vs $85.02M).
- NRXS has outperformed CV by 88.3 percentage points over the past year.
- The two companies sit in different sectors: CapsoVision in Health Care and Neuraxis in Healthcare.
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Healthcare · Biotechnology · 24 employees
CV vs NRXS FAQ
Which is bigger, CapsoVision or Neuraxis?
CapsoVision (CV) is larger, with a market capitalization of $352.25M compared with $85.02M for Neuraxis (NRXS).
Which stock has performed better over the past year, CV or NRXS?
NRXS returned +127.14% over the past 12 months, compared with +38.85% for CV (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and Neuraxis in the same industry?
No. CapsoVision is in the Health Care sector, while Neuraxis is in Healthcare.